Navigation Links
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Date:6/5/2008

- Phase II Data Indicate Overall and Disease-Free Survival -

WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

Results from the Phase II study (ASCO abstract #20027) show that 60 percent of the 45 high-risk patients enrolled in the trial experienced disease-free survival and 64 percent of patients achieved overall survival at 21 months.

"Previous findings suggest that sargramostim may be a potential adjuvant therapy for high-risk melanoma patients," said E. George Elias M.D., Ph.D., Director of Maryland Melanoma Center. "The percentage of patients who achieved disease-free and overall survival in this trial provides further evidence that sargramostim may prove to be a viable treatment option for this patient population and that further study in Phase III trials are needed."

In this trial, adjuvant therapy with Leukine and a synergistic cytokine, IL-2, was generally well-tolerated in patients with high-risk melanoma following potentially curative surgery. Each patient received two years of adjuvant therapy: year one with Leukine and IL-2 and year two with only Leukine. Toxicities were mild to moderate and no hospitalizations were required.

"These data, particularly the overall survival rates, are encouraging, even though preliminary, and indicate Leukine's potential as a treatment in this setting," said Paul MacCarthy, M.D., FRCPI, vice president and head of U.S. Medical Affairs for Bayer HealthCare Pharmaceuticals.

Clinical Trial Overview

This Phase II trial was a single-arm, open-labeled study to evaluate the safety, tolerability and treatment efficacy of Leukine and I
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
4. Wound Management Technologies, Inc. Announces Evidence Based Study
5. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Study Findings Show Infection Control Intervention Helps Keep Kids in School
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Pharmacyclics, Inc. ... that The New England Journal of Medicine ... 1b/2 study evaluating the investigational oral Bruton,s tyrosine kinase ... leukemia (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib was ... relapsed/refractory CLL or SLL, even in patients who were ...
(Date:6/19/2013)... BELLEVUE, Wash. , June 19, 2013 ... Provisioning version 4.0, a solution designed to ... to applications and data while supporting their ... release of Provisioning represents a milestone in ... governance and analytics capabilities for health systems. ...
(Date:6/19/2013)... June 19, 2013 ... added DrugPatentWatch to its extensive list ...      (Logo: http://photos.prnewswire.com/prnh/20130128/590935) , ... on pharmaceutical, drug patents and their ... critical business functions of patent agents ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 2Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 3Drug Patent Watch 2Drug Patent Watch 3
(Date:6/20/2013)... Bournemouth, Dorset (PRWEB) June 20, 2013 ... disease) and more serious medical conditions because they do ... of Eludril mouthwash and Elgydium toothpaste. , Seven million ... leaving it 48 hours between brushes, latest data from ... per cent of people polled by the BDHF also ...
(Date:6/20/2013)... Michigan-based natural health and wellness coach ... Hamilton which revealed that performing random acts of kindness ... release of the feel-good hormone Oxytocin in the brain ... the ‘cardio protective’ hormone because it temporarily lowers blood ... , “Being kind is something we can all do, ...
(Date:6/20/2013)... (PRWEB) June 20, 2013 Startups who ... energize their sales or test new markets, and international ... now have a new sales outsourcing company ... sales revenue. , Strategy Sales Partners is ... Founded by business owners for business owners, Strategy Sales ...
(Date:6/20/2013)... Creighton University was named to the ... the highest federal recognition a college or university can ... and civic engagement as well as meaningful community outcomes. ... and Community Service, is given to 690 schools nationwide ... Creighton is based on spiritual growth through service to ...
(Date:6/19/2013)... With the winter season having begun ... winter season Santiago day trips schedule. Offering ... and around Santiago this season, expert mountain guides from ... for backcountry skiing, challenging rock climbing adventures, and trekking ... dreamed of skiing in Chile , Chile Montaña ...
Breaking Medicine News(10 mins):Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 2Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 3Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 2Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 3Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3
... Canadian Study finds that adolescence boys are at higher risk ... Researchers have found that the seeds of hypertension and its ... management, lack of exercise, obesity are some of the factors ... in heart damages. ,In the study which began ...
... following an E. coli outbreak. In the last fortnight, at ... diarrhea. They were diagnosed with E coli infection. ... Inc in New Jersey have been incriminated as the most ... that they had eaten from one of the three Taco ...
... its annual meeting at Nashville on 4 th December. ... for// the need to move in a new direction ... ,The panel consisted of representatives from academics, ... the delay in the development of novel treatments for ...
... Academy of Pediatrics blames inappropriate advertising to be the ... government to impose bans and restrictions on// advertising to ... of New Mexico's Doctor and the lead author of ... ads per year on television alone and increasingly are ...
... health awareness in rural areas - puppets.// ... Raje last week informs the rural poor on the ... shows and cultural programmes. ,The month-long 'Swasthaya ... health-related information with the help of local artistes in ...
... have fast food outlets in their site, thus giving an ... reality it is not. According to a report in the// ... 200 hospitals had fast food outlets. ,Dr. Hannah ... two different messages by being in the health care profession ...
Cached Medicine News:Health News:Teen Boys At Greater Risk To High Blood Pressure Than Girls 2Health News:Research In A New Direction To Develop Innovative Psychotropic Drugs 2Health News:Research In A New Direction To Develop Innovative Psychotropic Drugs 3
... is the aqueous ... It is a fast-acting, ... gram-positive and gram-negative bacteria ... as well as most ...
... the one-step prep solution, allows the user ... applies and dries in less than 2-minutes. ... commonly used in surgical scrubbing and healthcare ... added to help provide a tacky surface ...
... designed for individual application and are ideal ... nursing homes, home healthcare settings, blood banks, ... departments. This unit dose pouch contains hydrogen ... and cleansing agent. Hydrogen Peroxide's chief value ...
... This multi-purpose topical solution ... Povidone Iodine Prep Spray is ... the possibility of cross contamination. ... an alternate method to the ...
Medicine Products: